Bio-Techne (TECH) Stock Overview
Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TECH Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Bio-Techne Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$61.86 |
| 52 Week High | US$80.80 |
| 52 Week Low | US$46.01 |
| Beta | 1.48 |
| 1 Month Change | 20.07% |
| 3 Month Change | 18.92% |
| 1 Year Change | -13.17% |
| 3 Year Change | -12.65% |
| 5 Year Change | -7.83% |
| Change since IPO | 9,556.20% |
Recent News & Updates
Recent updates
Bio-Techne: Coveted Life Sciences Asset On Sale Due To Academic Pressures
Aug 05Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)
Jul 28
What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?
May 29Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?
Apr 28Market Participants Recognise Bio-Techne Corporation's (NASDAQ:TECH) Earnings
Apr 07Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Feb 27Here's Why Bio-Techne (NASDAQ:TECH) Can Manage Its Debt Responsibly
Jan 21At US$71.48, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jan 03Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price
Dec 15There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings
Nov 06
Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges
Bio-Techne's investment in advanced diagnostics and specialized instruments like Leo suggests strong potential for revenue growth from increased sales and market adoption.Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04Shareholder Returns
| TECH | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 5.5% | 3.0% | 1.7% |
| 1Y | -13.2% | -13.5% | 14.4% |
Return vs Industry: TECH matched the US Life Sciences industry which returned -13.5% over the past year.
Return vs Market: TECH underperformed the US Market which returned 14.5% over the past year.
Price Volatility
| TECH volatility | |
|---|---|
| TECH Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TECH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TECH's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 3,100 | Kim Kelderman | www.bio-techne.com |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Bio-Techne Corporation Fundamentals Summary
| TECH fundamental statistics | |
|---|---|
| Market cap | US$9.59b |
| Earnings (TTM) | US$73.36m |
| Revenue (TTM) | US$1.22b |
Is TECH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TECH income statement (TTM) | |
|---|---|
| Revenue | US$1.22b |
| Cost of Revenue | US$408.52m |
| Gross Profit | US$811.12m |
| Other Expenses | US$737.75m |
| Earnings | US$73.36m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 66.50% |
| Net Profit Margin | 6.02% |
| Debt/Equity Ratio | 18.0% |
How did TECH perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 04:13 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-Techne Corporation is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Wasserman | Benchmark Company |